For Media

Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.

8833678833498825208824198822958819398817698796238717088659697903e58e-b2b9-4ada-b043-97e80d729fcf8306c524-7026-46f7-a180-77568626f59db2cfa434-183d-4956-b853-d462d1ebf740be249fe0-e30c-4faf-9641-0a5a0c5c3f25ed04a159-2fd3-42f8-858b-c785bda68ab3ac4b942f-7dac-488d-87c9-639895549133b19fbe31-80e0-4aa4-8422-cc0127fe6b5fe2050dd2-0c55-4980-9dc9-45f9effe6f565fad29f7-f96a-4a15-82e1-bc62530a444b37630afb-c541-47b6-84cf-44fc311a1796ARGS_News_2016_3_29_General_Releases.pdfARGS_News_2016_3_29_General_Releases.pdfARGS_News_2016_3_23_General_Releases.pdfARGS_News_2016_3_22_General_Releases.pdfARGS_News_2016_3_22_General_Releases.pdfARGS_News_2016_3_18_General_Releases.pdfARGS_News_2016_3_17_General_Releases.pdfARGS_News_2016_3_7_General_Releases.pdfARGS_News_2016_1_20_General_Releases.pdfARGS_News_2015_12_10_General_Releases.pdf7199269051359211038108411086710389121181657317693123456789102016-3-29T18:12:30-4:02016-3-29T16:30:14-4:02016-3-23T8:0:0-4:02016-3-22T16:5:0-4:02016-3-22T8:0:0-4:02016-3-18T8:0:0-4:02016-3-17T8:0:0-4:02016-3-7T8:31:16-4:02016-1-20T8:30:0-4:02015-12-10T8:0:0-4:0962585962569961895961802961660961302961137959072950920946488General ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesCancer Research Network of Nebraska is enrolling patients in this individualized immunotherapy studyCompany's chief scientific officer will join a panel discussion on therapies that stimulate the immune system in cancer patientsPoster presentation to examine immune response in HIV patients receiving AGS-004, the company's investigational immunotherapy for HIV.Company will present update on clinical development of immunotherapies based on Arcelis® technology platformArgos Therapeutics to Host Conference Call With Principal Investigator Dr. Robert Figlin on Thursday, December 10, 2015 at 5:00pm ESTCORRECTION -- Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational HighlightsArgos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational HighlightsArgos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care ChemotherapyArgos Therapeutics to Host Fourth Quarter and Full-Year 2015 Financial Results Conference Call on Tuesday, March 29, 2016Argos Therapeutics to Participate in 6th Annual "Cancer Immunotherapy: A Long-Awaited Reality" ConferenceArgos Therapeutics to Present at 2016 Keystone Symposia Conference "HIV Persistence: Pathogenesis and Eradication"Argos Therapeutics to Participate in Alliance for Regenerative Medicine Cell and Gene Therapy Investor DayArgos Therapeutics Announces Financing of Up to $60 MillionDr. Lee F. Allen Joins Argos Therapeutics as Chief Medical OfficerIndependent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis1301301301301301301301301301302016201620162016201620162016201620162015No Error0

CORRECTION -- Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
Read more

Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
Read more

Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care Chemotherapy
Read more

Argos Therapeutics to Host Fourth Quarter and Full-Year 2015 Financial Results Conference Call on Tuesday, March 29, 2016
Read more

Argos Therapeutics to Participate in 6th Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference
Read more

Argos Therapeutics to Present at 2016 Keystone Symposia Conference "HIV Persistence: Pathogenesis and Eradication"
Read more

Argos Therapeutics to Participate in Alliance for Regenerative Medicine Cell and Gene Therapy Investor Day
Read more

Argos Therapeutics Announces Financing of Up to $60 Million
Read more

Dr. Lee F. Allen Joins Argos Therapeutics as Chief Medical Officer
Read more

Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis
Read more